Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Randomized Controlled Trial to Evaluate the Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec in Participants With Moderate COVID-19 Disease

NCT04847583 is registered in ClinicalTrials.gov with Qurient Co., Ltd. as lead sponsor.

NCT NCT04847583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04847583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Randomized Controlled Trial to Evaluate the Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec in Participants With Moderate COVID-19 Disease
Lead sponsor
Qurient Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
July 29, 2021
Completion date
February 11, 2022
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 virus infection